<DOC>
	<DOC>NCT03000569</DOC>
	<brief_summary>This study will assess the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in up to 30 subjects with Parkinson's Disease of Moderate Severity.</brief_summary>
	<brief_title>A Study to Evaluate SAGE-217 in Patients With Parkinson's Disease of Moderate Severity</brief_title>
	<detailed_description>Part A of the study is an open-label design with dosing of Levodopa for 3 days followed by SAGE-217 for 4 days. Part B of the study is a randomized, placebo-controlled, two-sequence crossover design. Eligible subjects will be randomized to open-label Levodopa plus blinded SAGE-217 or placebo for Period 1 (4 days). In Period 2 (4 days) all subjects will receive open-label SAGE-217 for 4 days.</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Subject has a diagnosis of idiopathic Parkinson's Disease (Hoehn and Yahr Stage 2 or Stage 3) with a duration of less than 7 years prior to screening Subject is on a stable dose (at least 1 month prior to baseline visit) of an antiparkinsonian agent including immediaterelease oral Levodopa or CarbidopaLevodopa and is willing to remain on this dose for the duration of the study Subject has early (Hoehn and Yahr Stage 1) or advanced (Hoehn and Yahr Stage 4 or Stage 5) Parkinson's Disease Subject with presence of druginduced parkinsonism, metabolic identified neurogenetic disorders, encephalitis, or other atypical Parkinsonian syndromes Medical history of electroconvulsive therapy or stereotaxic brain surgery for Parkinson's Disease Medical history of suicide attempt within 2 years of screening or current suicidal ideation Medical history of impulse control disorder</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Parkinson</keyword>
</DOC>